Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome
- PMID: 12163791
- DOI: 10.1097/00003246-200208000-00016
Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome
Abstract
Objective: Trials of potential new therapies in acute lung injury are difficult and expensive to conduct. This article is designed to determine the utility, behavior, and statistical properties of a new primary end point for such trials, ventilator-free days, defined as days alive and free from mechanical ventilation. Describing the nuances of this outcome measure is particularly important because using it, while ignoring mortality, could result in misleading conclusions.
Design: To develop a model for the duration of ventilation and mortality and fit the model by using data from a recently completed clinical trial. To determine the appropriate test statistic for the new measure and derive a formula for power. To determine a formula for the probability that the test statistic will reject the null hypothesis and mortality will simultaneously show improvement. To plot power curves for the test statistic and determine sample sizes for reasonable alternative hypotheses.
Setting: Intensive care units.
Patients: Patients with acute respiratory distress syndrome or acute lung injury as defined by the American-European Consensus Conference.
Main results: The proposed model fit the clinical data. Ventilator-free days were improved by lower tidal volume ventilation, but the improvement was mostly caused by the improved mortality rate, so trials that expected similar effects would only have modest increase in power if they used ventilator-free days as their primary end point rather than 28-day mortality. Similar results were obtained using the model in two groups segregated by low or high Acute Physiology and Chronic Health Evaluation score. On the other hand, if patients are divided into two groups on the basis of the lung injury score, both the duration of ventilation and mortality are lower in the low lung injury score group. A trial of a treatment that had a similar clinical effect would have a large increase in power, allowing for a reduction in the required sample size.
Conclusions: Use of ventilator-free days as a trial end point allows smaller sample sizes if it is assumed that the treatment being tested simultaneously reduces the duration of ventilation and improves mortality. It is unlikely that a treatment that led to higher mortality could lead to a statistically significant improvement in ventilator-free days. This would be especially true if the treatment were also required to produce a nominal improvement in mortality.
Similar articles
-
Failure to Improve the Oxygenation Index Is a Useful Predictor of Therapy Failure in Acute Respiratory Distress Syndrome Clinical Trials.Crit Care Med. 2016 Jan;44(1):e40-4. doi: 10.1097/CCM.0000000000001295. Crit Care Med. 2016. PMID: 26427588 Free PMC article.
-
Low stretch ventilation strategy in acute respiratory distress syndrome: eight years of clinical experience in a single center.Crit Care Med. 2003 Mar;31(3):765-9. doi: 10.1097/01.CCM.0000055402.68581.DC. Crit Care Med. 2003. PMID: 12626981
-
Air cysts and bronchiectasis prevail in nondependent areas in severe acute respiratory distress syndrome: a computed tomographic study of ventilator-associated changes.Crit Care Med. 2002 Aug;30(8):1747-52. doi: 10.1097/00003246-200208000-00012. Crit Care Med. 2002. PMID: 12163787
-
Low Tidal Volume versus Non-Volume-Limited Strategies for Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.Ann Am Thorac Soc. 2017 Oct;14(Supplement_4):S271-S279. doi: 10.1513/AnnalsATS.201704-337OT. Ann Am Thorac Soc. 2017. PMID: 28846440 Review.
-
Lung protective ventilation strategy for the acute respiratory distress syndrome.Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003844. doi: 10.1002/14651858.CD003844.pub3. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2013 Feb 28;(2):CD003844. doi: 10.1002/14651858.CD003844.pub4. PMID: 17636739 Updated. Review.
Cited by
-
Prognostic Value of Consolidation in Lung Tomography in Patients With Acute Respiratory Distress Syndrome.Open Respir Arch. 2024 Sep 24;6(4):100366. doi: 10.1016/j.opresp.2024.100366. eCollection 2024 Oct-Dec. Open Respir Arch. 2024. PMID: 39484662 Free PMC article. No abstract available.
-
Diastolic dysfunction and mortality in early severe sepsis and septic shock: a prospective, observational echocardiography study.Crit Ultrasound J. 2012 May 4;4(1):8. doi: 10.1186/2036-7902-4-8. Crit Ultrasound J. 2012. PMID: 22870900 Free PMC article.
-
Tumor necrosis factor -308 polymorphism (rs1800629) is associated with mortality and ventilator duration in 1057 Caucasian patients.Cytokine. 2012 Oct;60(1):249-56. doi: 10.1016/j.cyto.2012.06.016. Epub 2012 Jun 28. Cytokine. 2012. PMID: 22749237 Free PMC article.
-
What Awaits on the Other Side: Post-Lung Transplant Morbidity and Mortality After Pre-Transplant Hospitalization.Ann Transplant. 2020 Aug 18;25:e922641. doi: 10.12659/AOT.922641. Ann Transplant. 2020. PMID: 32807766 Free PMC article.
-
Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial.JAMA. 2015 Jan 27;313(4):379-89. doi: 10.1001/jama.2014.18399. JAMA. 2015. PMID: 25602358 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources